Braun Stacey Associates Inc. Buys 12,657 Shares of Neurocrine Biosciences, Inc. $NBIX

Braun Stacey Associates Inc. lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.4% during the third quarter, HoldingsChannel.com reports. The fund owned 183,027 shares of the company’s stock after purchasing an additional 12,657 shares during the period. Braun Stacey Associates Inc.’s holdings in Neurocrine Biosciences were worth $25,693,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its stake in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after purchasing an additional 135 shares in the last quarter. MAI Capital Management boosted its position in shares of Neurocrine Biosciences by 101.2% during the second quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after purchasing an additional 165 shares in the last quarter. True Wealth Design LLC grew its holdings in shares of Neurocrine Biosciences by 1,215.4% in the 2nd quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after buying an additional 316 shares during the period. Huntington National Bank increased its position in shares of Neurocrine Biosciences by 26.4% in the 2nd quarter. Huntington National Bank now owns 604 shares of the company’s stock valued at $76,000 after buying an additional 126 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth $97,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $141.83 on Friday. The firm has a market cap of $14.14 billion, a PE ratio of 33.93, a P/E/G ratio of 0.93 and a beta of 0.28. The business’s 50 day simple moving average is $147.03 and its 200 day simple moving average is $139.17. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $160.18.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $794.90 million during the quarter, compared to analysts’ expectations of $746.61 million. During the same period last year, the business earned $1.81 EPS. The business’s quarterly revenue was up 27.8% on a year-over-year basis. As a group, equities research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NBIX. Piper Sandler lifted their target price on Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. TD Cowen raised their price target on Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. HC Wainwright boosted their price objective on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Wedbush reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, September 22nd. Finally, Royal Bank Of Canada lifted their price target on shares of Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $175.25.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 300 shares of Neurocrine Biosciences stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total value of $42,591.00. Following the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $19,933,581.79. The trade was a 0.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director William H. Rastetter sold 18,000 shares of the business’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $151.82, for a total transaction of $2,732,760.00. Following the sale, the director directly owned 40,360 shares in the company, valued at $6,127,455.20. This trade represents a 30.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 43,866 shares of company stock valued at $6,570,237 in the last quarter. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.